ADA 2020: Ertugliflozin May Reduce Risk of Hospitalization for Heart Failure in Type 2 Diabetes Patients With Atherosclerotic Cardiovascular Disease
VERTIS-CV trial failed to meet its primary endpoint of time to major adverse cardiovascular events
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.